IDO2 Antibody (OTI1A4) [DyLight 550]
Novus Biologicals, part of Bio-Techne | Catalog # NBP2-72453R
Conjugate
Catalog #
Forumulation
Catalog #
Key Product Details
Species Reactivity
Validated:
Human
Applications
Flow Cytometry, Western Blot
Label
DyLight 550 (Excitation = 562 nm, Emission = 576 nm)
Antibody Source
Monoclonal Mouse IgG1 Clone # OTI1A4
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Product Summary for IDO2 Antibody (OTI1A4) [DyLight 550]
Immunogen
Full length recombinant protein of human IDO2 (NP_919270) produced in HEK293T cells.
Clonality
Monoclonal
Host
Mouse
Isotype
IgG1
Applications for IDO2 Antibody (OTI1A4) [DyLight 550]
Application
Recommended Usage
Flow Cytometry
Optimal dilutions of this antibody should be experimentally determined.
Western Blot
Optimal dilutions of this antibody should be experimentally determined.
Application Notes
Optimal dilution of this antibody should be experimentally determined.
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Immunogen affinity purified
Formulation
50mM Sodium Borate
Preservative
0.05% Sodium Azide
Concentration
Please see the vial label for concentration. If unlisted please contact technical services.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Store at 4C in the dark.
Background: IDO2
Long Name
Indoleamine 2,3-dioxygenase 2
Alternate Names
Ido-2, INDOL1, Indoleamine 2,3-dioxygenase-2
Gene Symbol
IDO2
Additional IDO2 Products
Product Documents for IDO2 Antibody (OTI1A4) [DyLight 550]
Product Specific Notices for IDO2 Antibody (OTI1A4) [DyLight 550]
DyLight (R) is a trademark of Thermo Fisher Scientific Inc. and its subsidiaries.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...